Someit Sidhu, JATT (Pathios Therapeutics)

An­oth­er life sci­ences SPAC has popped up from a small biotech CEO with the help of Take­da, No­var­tis vet­er­ans

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

The SPAC train has slowed down since the ex­tra­or­di­nar­i­ly high lev­els from late 2020 in­to ear­ly this year, but Tues­day saw the fil­ing of a new blank-check com­pa­ny tar­get­ing the life sci­ences in­dus­try.

JATT Ac­qui­si­tion sub­mit­ted its SEC pa­per­work Tues­day, pen­cil­ing in an es­ti­mat­ed raise of $120 mil­lion as it sets its sights on a re­verse merg­er part­ner. The SPAC is run by Someit Sid­hu, a co-founder of Pathios Ther­a­peu­tics, as well as CEO of Akaza Bio­science and Izana Bio­science. Sid­hu will con­trol about 97% of the blank-check com­pa­ny’s shares, per the S-1.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.